Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E (specifically alpha-tocopherol or its esters, like alpha tocopheryl acetate) has been studied as a supportive treatment in certain forms of hepatitis, especially nonalcoholic steatohepatitis (NASH), which is a subset of nonalcoholic fatty liver disease (NAFLD). The scientific rationale is based on Vitamin E's antioxidant properties, which may help reduce oxidative stress and liver cell injury associated with these conditions. Several randomized controlled trials, such as the PIVENS trial (Sanyal et al., 2010, NEJM), have shown that high-dose Vitamin E supplementation (800 IU/day) improved some histological features of NASH in non-diabetic adults. This led to guidelines from organizations like the American Association for the Study of Liver Diseases (AASLD) recommending Vitamin E for certain adults with biopsy-proven NASH. However, for other forms of hepatitis—such as viral hepatitis B or C—evidence for Vitamin E as a therapeutic agent is limited and less convincing. Most clinical guidelines do not support its use for these types. The overall quality of evidence is moderate for NASH and weak or absent for other forms of hepatitis. Furthermore, safety concerns exist regarding long-term high-dose Vitamin E supplementation, including a possible increased risk of all-cause mortality and hemorrhagic stroke. In summary, Vitamin E has a scientifically supported but limited role in specific liver conditions like NASH, but is not broadly validated for hepatitis in general.

More about Vitamin E (alpha tocopheryl acetate)
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by Vitamin E (alpha tocopheryl acetate)

Products containing Vitamin E (alpha tocopheryl acetate)